PTGX
#961
Protagonist Therapeutics, Inc. - Common Stock
144.3 3 USD
-0.03%
Market Price
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
Year Range
Daily Change
-3.46%
Monthly Change
+9.53%
6 month change
+56.74%
Year Change
+92.11%
Previous Close
149.5 0
Open
144.3 3
Low
144.3 3
High
144.3 3
Volume
128
Financials
- Market Capitalization 9.34 B
- Employee 141
- Founded 2006
- CEO N/A
- Website www.protagonist-inc.com
- Headquarter Delaware, United States
- FIGI BBG002B63KM7
- Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-42.6
Price to sales ratio
120.66
Related tickers
| # | Name | Price | 24h % | 7d % | 1M % | 1Y % | Market Cap | Last 7 Days | |
|---|---|---|---|---|---|---|---|---|---|
| 931 |  KYMR Kymera Therapeutics, Inc. - Common Stock | 118.15 USD | -1.73% | -0.39% | +11.82% | +99.92% | 9.82 B USD | ||
| 940 |  PRAX Praxis Precision Medicines, Inc. - Common Stock | 344.75 USD | -6.28% | -6.79% | +15.50% | +664.41% | 9.63 B USD | ||
| 982 |  CRNX Crinetics Pharmaceuticals, Inc. - Common Stock | 84.84 USD | -0.01% | +0.15% | +1.08% | +106.42% | 9.00 B USD | ||
| 990 |  PCVX Vaxcyte, Inc. - Common Stock | 59.84 USD | -2.16% | -3.95% | +13.01% | +41.47% | 8.90 B USD |
Frequently asked questions about Protagonist Therapeutics, Inc
What is the Protagonist Therapeutics, Inc stock price today?
The current price of Protagonist Therapeutics, Inc (PTGX) is 144.33. Over the past 24 hours, the stock has changed by -3.46%. Follow the PTGX chart for real-time price dynamics.
What is the stock ticker of Protagonist Therapeutics, Inc?
Protagonist Therapeutics, Inc trades under the ticker PTGX. Tickers can differ by exchange, so always check the exchange and instrument details before trading.
Is Protagonist Therapeutics, Inc stock going up?
PTGX has changed by -6.47% over the last week, +9.53% over the last month, and +92.11% over the last year. Review the chart to see whether the current move is part of a broader trend.
What is the market capitalization of Protagonist Therapeutics, Inc?
Protagonist Therapeutics, Inc currently has a market capitalization of 9.34 B. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.
What were Protagonist Therapeutics, Inc earnings last quarter?
Last quarter, Protagonist Therapeutics, Inc reported earnings of 2.47 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.
What was Protagonist Therapeutics, Inc revenue for the last quarter?
Protagonist Therapeutics, Inc reported quarterly revenue of 213.47 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.
What was Protagonist Therapeutics, Inc net income for the last quarter?
Protagonist Therapeutics, Inc reported net income of 162.85 M for the last quarter. The previous quarter showed 3.78 M, which means net income changed by +4204.76%.
How many employees does Protagonist Therapeutics, Inc have?
As of the latest available data, Protagonist Therapeutics, Inc has 141 employees. Workforce size can provide additional context about the company's scale and operations.
What is Protagonist Therapeutics, Inc EBITDA?
Protagonist Therapeutics, Inc EBITDA is 159.16 M, and its EBITDA margin is 74.56%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.
How can I buy Protagonist Therapeutics, Inc stock?
You can buy Protagonist Therapeutics, Inc (PTGX) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.
Should I invest in Protagonist Therapeutics, Inc stock?
Investing in Protagonist Therapeutics, Inc requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the PTGX chart and related analysis on metatrader.com as part of your research.